Lymphatic ERG signaling in scleroderma fibrosis07/07/2022 - 05/31/2027 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R01AR080950-03
GATA-6 in pulmonary arterial hypertension03/05/2020 - 01/31/2025 (PI)
NIH/National Heart, Lung, and Blood Institute5R01HL150638-04
Functional characterization of aberrant PD-1+TIGIT+ T cell subsets expanded in SSc patients08/01/2022 - 09/30/2023 (Subcontract PI)
National Jewish Health Scleroderma Fdn
Regulation of lymphatic system in scleroderma04/01/2020 - 09/30/2022 (PI)
Scleroderma Foundation
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis09/22/2017 - 08/31/2022 (Subcontract PI)
The University of Pittsburgh NIH NIAMS5P50AR060780-10
Molecular mechanism of vasculopathy and fibrosis in scleroderma05/06/2014 - 04/30/2020 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R01AR042334-24
Preclinical assesment of dimethylfumarate (Tecfidera) as a novel therapeutic for SSC-PAH04/01/2017 - 09/30/2019 (PI)
Scleroderma Foundation
TGF -beta receptor/Endoglin signaling and the origin of scleroderma fibroblasts09/01/2015 - 08/31/2017 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases2R56AR044883-16
NIAMS: CORT09/01/2011 - 08/31/2017 (Sub-Project Level Key Person)
PI:
Robert W. Simms, MDNIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5P50AR060780-05
The Functional Biology of Oncostatin M (OSM) and Interleukin (IL)-6/ Soluble IL-6 Receptor in Endothelial Cells08/24/2015 - 08/23/2016 (PI)
GlaxoSmithKline Research & Development Limited
Showing 10 of 12 results.
Show All Results
TGF-Beta Receptor Signaling Scleroderma10/01/2009 - 05/31/2014 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R01AR044883-15
The Molecular Mechanisms of Fibrosis08/10/1994 - 03/31/2013 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R01AR042334-19